• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Anticoagulation: Updated Guidelines for Outpatient Management.
Abstract Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for patients with mechanical valves and valvular atrial fibrillation. Vitamin K antagonists inhibit the production of vitamin K-related factors and require a minimum of five days overlap with parenteral anticoagulants, ...
Source: American Family Physician - September 30, 2019 Category: Primary Care Authors: Wigle P, Hein B, Bernheisel CR Tags: Am Fam Physician Source Type: research

Problem-patients in HRT
Since the Women's Health Initiative (WHI) has been stopped 2002 due to increased risk of venous thromboembolism, myocardial infarction, stroke and breast cancer, safety issues have got great concern using hormone replacement therapy (HRT). However, using lower dosages, other hormonal components and/or transdermal instead of oral application can reduce those risks although not demonstrated in a placebo-controlled study comparable to WHI. However, this has been shown in large case/control- and cohort-studies reflecting more practical conditions in contrast to WHI.
Source: Maturitas - May 14, 2019 Category: Primary Care Authors: Alfred O. Mueck Tags: INV65 Source Type: research

French Intensive Care Society, International congress - Réanimation 2016.
C, Sauneuf B, Verrier P, Pottier V, Orabona M, Samba D, Viquesnel G, Lermuzeaux M, Hazera P, Hanouz JL, Parienti JJ, Du Cheyron D, Demoule A, Clavel M, Rolland-Debord C, Perbet S, Terzi N, Kouatchet A, Wallet F, Roze H, Vargas F, Guérin C, Dellamonica J, Jaber S, Similowski T, Quenot JP, Binquet C, Vinsonneau C, Barbar SD, Vinault S, Deckert V, Lemaire S, Hssain AA, Bruyère R, Souweine B, Lagrost L, Adrie C, Jung B, Daurat A, De Jong A, Chanques G, Mahul M, Monnin M, Molinari N, Lheureux O, Trepo E, Hites M, Cotton F, Wolff F, Surin R, Créteur J, Vincent JL, Gustot T, Jacobs F, Taccone FS, Neuville M, Timsit JF, El-Hel...
Source: Australian Family Physician - May 31, 2016 Category: Primary Care Authors: Jaillette E, Girault C, Brunin G, Zerimech F, Chiche A, Broucqsault-Dedrie C, Fayolle C, Minacori F, Alves I, Barrailler S, Robriquet L, Delaporte E, Thellier D, Delcourte C, Duhamel A, Nseir S, Valette X, Desmeulles I, Savary B, Masson R, Seguin A, Daubi Tags: Ann Intensive Care Source Type: research

Hormone therapy and venous thromboembolism among postmenopausal women
Despite a decrease in postmenopausal hormone therapy (HT) use during the last decade, many women are still prescribed this treatment which remains the most effective to counteract climacteric symptoms. However, HT increases the risk of breast cancer, stroke and venous thromboembolism (VTE) which represents the major harmful effect of short-term duration use. Nevertheless, this benefit/risk ratio has been established among women using oral estrogens alone or combined with a specific progestogen and cannot be necessary extrapolated to other HT.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Marianne Canonico Tags: INV32 Source Type: research

Approach to the new oral anticoagulants in family practice: Part 2: addressing frequently asked questions.
CONCLUSION: Management of "what if" scenarios for patients taking NOACs have been proposed, but additional study is needed to address these issues, especially periprocedural management and bleeding. PMID: 25392439 [PubMed - as supplied by publisher]
Source: Canadian Family Physician Medecin de Famille Canadien - November 1, 2014 Category: Primary Care Authors: Douketis J, Bell AD, Eikelboom J, Liew A Tags: Can Fam Physician Source Type: research

Combined hormonal contraception
Abstract: Combined oral contraception is now available as oral, transdermal, vaginal and injectable preparations. Only the pill and patch are currently marketed in the UK. Most of the data come from the oral preparation (the combined pill), which has been marketed for more than 40 years and used by millions of women. Used perfectly, combined hormonal contraception is highly effective (failure rate 1/1000), because it works by inhibiting ovulation. In typical use, however, mistakes are made, and pill failure rates are about 8%. Serious cardiovascular side-effects (heart attack, stroke and venous thromboembolism) are ra...
Source: Women's Health Medicine - November 1, 2006 Category: Primary Care Authors: Anna Glasier Source Type: research